Events

SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.

The 96-week results presented at the CMSC Annual Meeting in Phoenix highlight fenebrutinib’s potential as a first-in-class reversible Bruton’s tyrosine kinase (BTK) inhibitor in the multiple sclerosis space. This development is poised to influence treatment paradigms, particularly as Phase III results approach later this year.

Sustained Disease Control With No Observed Disability Progression

SHERIDAN, WYOMING – May 27, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has launched its 2025/26 financial year with exceptional results, driven by its standout performance at China Print 2025 in Beijing. The company’s strategic emphasis on packaging and digital printing proved highly effective, resulting in the sale of nearly 350 printing units—well above expectations—and setting a solid course for continued growth in the Asian market.

Strong Demand Underscores HEIDELBERG’s Market Leadership

Attracting around 120,000 attendees and over 1.3 million online viewers, China Print reaffirmed its status as the region’s premier print industry event. HEIDELBERG recorded the highest visitor numbers at the show, where customers from across Asia expressed robust interest in the company’s end-to-end printing solutions.

SHERIDAN, WYOMING – May 27, 2025 – In a pivotal move to diversify its production capabilities, Plural Industria Grafica LTDA, one of South America's leading offset printing firms, has integrated sheetfed offset technology from Heidelberger Druckmaschinen AG (HEIDELBERG) into its operations for the first time. This landmark decision underscores Plural's commitment to capturing new market segments and enhancing cost-efficiency for shorter print runs.

Expanding Beyond Traditional Web Offset

Based in Santana de Parnaíba, São Paulo, Plural has long been a dominant force in web offset printing, serving sectors from publishing to commercial and security printing. With its newly installed Speedmaster XL 106-8-P+L and the 100th unit of the fourth-generation CutStar reel sheeter, the company is now targeting previously inaccessible market segments that demand shorter run lengths.

SHERIDAN, WYOMING – May 27, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has successfully navigated a challenging economic landscape, achieving its fiscal year 2024/25 targets while laying the groundwork for further growth in 2025/26. The company maintained a stable adjusted EBITDA margin of 7.1 percent and generated a clearly positive free cash flow of around €50 million, despite rising wage costs, a slightly lower sales volume, and expenses related to the drupa trade fair.

Sales reached approximately €2.28 billion, just under the previous year’s €2.395 billion. The fourth quarter was a standout, with sales accelerating and the adjusted EBITDA margin doubling to around 10 percent compared to the prior year.

Resilient Financial Management and Profitability Focus

SHERIDAN, WYOMING – May 27, 2025 – Seaway Printing has taken a bold step toward fully autonomous production, becoming the first U.S. customer to implement HEIDELBERG’s Plate to Unit system, and integrating the world’s first Inline Splicer with the CutStar generation 4 sheeter. The move is part of a sweeping automation strategy aimed at significantly improving productivity and operational efficiency across Seaway’s expanded Wisconsin facility.

Located in De Pere, Wisconsin, Seaway recently doubled its production capacity to meet surging demand for short-run book and magazine printing. With new HEIDELBERG technology embedded in prepress, press, and postpress operations, the company now operates with fewer manual interventions and has optimized labor usage by allowing each machine to be managed by just one operator.

Breakthrough in Prepress and Plate Logistics

SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.

This development is underpinned by data from the phase III INAVO120 study, which demonstrated that the Itovebi-based regimen more than doubled progression-free survival compared to the standard treatment alone. The recommendation marks a key milestone toward potential European Commission approval, with broader implications for treatment standards across the region.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

This joint initiative is poised to establish SBX as a clinical mainstay in neonatal intensive care units (NICUs), helping identify genetic disorders in newborns with unprecedented speed and precision. It also positions both organizations to lead in delivering fast, scalable, and cost-efficient genomic insights that could redefine diagnostic and therapeutic practices.

Targeting Transformational Impact in Clinical Genomics

SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.

Landmark Survival Benefit in R/R DLBCL

The updated STARGLO data show a 40% improvement in overall survival for patients treated with Columvi plus GemOx (gemcitabine and oxaliplatin), compared to the control arm receiving MabThera®/Rituxan® (rituximab) with GemOx. Notably, the median overall survival for the Columvi arm was not reached, versus 13.5 months in the comparator group.

Further findings demonstrated:

SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.

The approval makes Susvimo the first and only FDA-approved continuous drug delivery system for DR, offering patients the potential to maintain vision with just one refill every nine months. This development adds a third approved indication for Susvimo, which is already cleared for neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced an encouraging update on its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx), following discussion by the FDA’s Oncologic Drugs Advisory Committee (ODAC). The combination therapy demonstrated a significant 41% reduction in the risk of death in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not candidates for autologous stem cell transplant.

Landmark survival data in STARGLO trial supports regulatory momentum

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.

Enhancing Treatment Precision in Lung Cancer Care

The VENTANA MET (SP44) RxDx Assay is the first FDA-approved companion diagnostic for detecting MET protein expression in NSQ-NSCLC patients. By identifying those with elevated levels of MET—a key predictive biomarker—the assay supports clinicians in selecting patients who are most likely to benefit from c-Met-targeted therapy.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced compelling final results from the decade-long APHINITY Phase III clinical trial, demonstrating a significant 17% reduction in the risk of death for patients with HER2-positive early-stage breast cancer who received a Perjeta® (pertuzumab)-based adjuvant therapy. These findings reinforce the strategic role of the Perjeta-based regimen in long-term disease management and will be presented as a late-breaking abstract at the 2025 ESMO Breast Cancer Congress.

Strategic Impact for High-Risk Patient Groups

The APHINITY study highlights even stronger benefits in a key subgroup: patients with lymph node-positive disease experienced a 21% reduction in mortality risk. This outcome strengthens the treatment’s position in clinical practice, especially for those at heightened risk of recurrence.

SHERIDAN, WYOMING – May 27, 2025 – Roche has introduced its Elecsys® PRO-C3 diagnostic test, marking a major step forward in the assessment of liver fibrosis severity, particularly in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). With the ability to deliver results in just 18 minutes, the new test is poised to streamline diagnostics and enable earlier, more accurate clinical decision-making.

Strategic Response to a Global Health Burden

MASLD, affecting approximately 30% of the global population, is increasingly prevalent due to rising rates of diabetes, obesity, and other cardiometabolic risk factors. While it contributes to around one in every 25 deaths globally, liver fibrosis associated with MASLD often progresses unnoticed until late stages, escalating risks of cirrhosis, liver failure, and cancer.

SHERIDAN, WYOMING – May 27, 2025 – ANGA COM, Europe’s premier business platform for broadband, television, and online media, is set to return from June 3 to 5, 2025, in Cologne, Germany, with a bold agenda designed to shape the future of digital infrastructure and content delivery across Europe and beyond.

With more than 480 exhibitors from 35 countries and over 23,000 participants expected, ANGA COM 2025 underscores its strategic importance as a hub for the broadband and media sectors. Anchored in the economic heart of Germany’s telecommunications industry, the event offers a dynamic meeting point for network operators, technology providers, and media stakeholders to forge partnerships, showcase innovation, and debate key industry trends.

A powerhouse gathering for broadband and content leaders

SHERIDAN, WYOMING – May 27, 2025 – Hettich is redefining the digital landscape of furniture manufacturing with the introduction of intuitive assembly technologies showcased at interzum 2025. The fittings specialist is highlighting its latest advancements in user-friendly digital tools—from augmented reality and QR code guidance to a debut 3D printing portal—designed to streamline operations and enhance productivity across workshops and production facilities.

Empowering Workflows Through Digital Innovation

Hettich’s interzum 2025 presence is centered on supporting modern fabricators with practical, mobile-enabled digital services. Built on a “Bring your own device” model, these tools grant instant access to step-by-step instructions, adjustment aids, and training videos through smartphones or tablets.

SHERIDAN, WYOMING – May 27, 2025 – Hettich is reshaping the future of space utilization with its award-winning SpinLines product family—a transformative suite of turning swivel systems designed to revolutionize how furniture and interiors function. Debuted in phases since 2019 and spotlighted at interzum 2023 and 2025, these innovative solutions enable unprecedented flexibility in residential and commercial design, offering new avenues for architects, fabricators, and furniture manufacturers.

From Turntable to Room Transformation

The journey began with a vision: rethinking how storage space is accessed and used. In collaboration with Chemnitz-based “WIRfinder” innovation network, Hettich developed the prototype ComfortSpin—a turntable that rotates cabinet or refrigerator contents to the front for easy access. The concept, rooted in translatory rotation, quickly gained traction among kitchen appliance makers and entered mass production in 2019.

SHERIDAN, WYOMING – May 27, 2025 – Hettich is reshaping the future of workspace design with its latest innovations unveiled at interzum 2025. Under the theme “Transforming Spaces – with innovative motion,” the company presents RoomSpin and SpinLines—modular systems that bring motion, flexibility, and architectural intelligence to contract furnishing.

At its “Space and Architecture” exhibit, Hettich introduces a holistic concept for rethinking how rooms and furniture function, offering transformative solutions for compact living, open-plan environments, public spaces, and retail. The focus: adaptive interiors guided by choreographed movement.

Agile Planning for Dynamic Environments

SHERIDAN, WYOMING – May 27, 2025 – Hettich is reaffirming its role as a global innovation leader in furniture fittings at interzum 2025, unveiling a strategically aligned portfolio that meets the evolving demands of trade professionals, furniture retailers, and manufacturers. The new offerings reflect a forward-looking vision centered on user convenience, functional performance, and market adaptability—spanning living, kitchen, workspace, and outdoor applications.

Elegant Innovation: Avosys Glass and Mirror Door Hinge

Designed for premium aesthetic integration, the new Avosys hinge delivers a discreet, high-performance solution for glass and mirror cabinets. With its sleek, compact design and narrow linear mounting plate, Avosys prioritizes interior space without compromising strength.

SHERIDAN, WYOMING – May 27, 2025 – Hettich, one of the world’s leading manufacturers of furniture fittings, is poised to reshape the future of interiors with its cutting-edge innovations and sustainability-driven initiatives showcased at interzum 2025. Under the visionary theme “Transforming Spaces – with innovative motion,” the company brings forward a portfolio that highlights its commitment to customer-centric design, strategic industry collaboration, and environmentally responsible business practices.

Expanding Innovation with Strategic Product Highlights

At the forefront of Hettich’s interzum 2025 presentation are several groundbreaking product introductions designed to enhance user experience, optimize space utilization, and support evolving industry demands:

SHERIDAN, WYOMING – May 27, 2025 – Ninkaplast GmbH (Ninka), a leading German supplier of injection-molded components for kitchen furniture, unveiled key product innovations at Interzum 2025 with the expansion of its modular waste bin systems, designed for under-sink installation and seamless integration into modern kitchen drawers.

With the debut of expanded variants in the “one2seven,” “one2eight,” and “one2nine” product lines, Ninka strengthens its value proposition for kitchen manufacturers seeking differentiation, operational flexibility, and improved consumer convenience. These developments highlight Ninka’s commitment to intelligent system design and compatibility across multiple drawer platforms.

Strategic Differentiation Through Flexible System Architecture